Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avner Reshef

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|November 24, 2012
C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studiesLynda Schneider, David Hurewitz, Richard Wasserman, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|April 14, 2021
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedemaHenriette Farkas, Avner Reshef, Teresa Caballero, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 29, 2016
Impact of an extended challenge on the effectiveness of β-lactam hypersensitivity investigationRoy Ratzon, Avner Reshef, Ori Efrati, et al.
Harefuah|May 27, 2026
[Angioedema 2025 - Advancements in Diagnosis and Treatment]Avner Reshef, Nancy Agmon Levin, Shira Ben Or, et al.
The World Allergy Organization Journal|January 24, 2014
Case Title: 45 year-old male with recurrent angioedema: WAO international case-based discussionsJennifer W Leiding, Douglas Beakes, Stephen C Dreskin, et al.
Harefuah|May 18, 2011
[Chronic rhinitis--clinical guidelines 2010]Avner Reshef, Mona Kidon-Yankovich, Ra'anan Cohen-Kerem, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2025
Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutationsDanny M Cohn, Avner Reshef, Petra Staubach, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2015
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacksH Henry Li, Dumitru Moldovan, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 12, 2017
Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary AngioedemaHenriette Farkas, Avner Reshef, Werner Aberer, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 12, 2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trialDonald S Levy, Henriette Farkas, Marc A Riedl, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|November 24, 2012
C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studiesLynda Schneider, David Hurewitz, Richard Wasserman, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|April 14, 2021
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedemaHenriette Farkas, Avner Reshef, Teresa Caballero, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 29, 2016
Impact of an extended challenge on the effectiveness of β-lactam hypersensitivity investigationRoy Ratzon, Avner Reshef, Ori Efrati, et al.
Harefuah|May 27, 2026
[Angioedema 2025 - Advancements in Diagnosis and Treatment]Avner Reshef, Nancy Agmon Levin, Shira Ben Or, et al.
The World Allergy Organization Journal|January 24, 2014
Case Title: 45 year-old male with recurrent angioedema: WAO international case-based discussionsJennifer W Leiding, Douglas Beakes, Stephen C Dreskin, et al.
Harefuah|May 18, 2011
[Chronic rhinitis--clinical guidelines 2010]Avner Reshef, Mona Kidon-Yankovich, Ra'anan Cohen-Kerem, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2025
Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutationsDanny M Cohn, Avner Reshef, Petra Staubach, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2015
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacksH Henry Li, Dumitru Moldovan, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 12, 2017
Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary AngioedemaHenriette Farkas, Avner Reshef, Werner Aberer, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 12, 2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trialDonald S Levy, Henriette Farkas, Marc A Riedl, et al.
Pageof 7